Publications by authors named "Helen Mackay"

Claim this Profile
E
Evaluation of Recurrence Rate in Canadian Patients With Stage II/III HR+/HER2- Early Breast Cancer in the Real-World Setting.
Karen Gambaro, Kahina Rachedi, Mark Basik, Fred Saad, Anne-Marie Mes-Masson, Helen Mackay

Breast Cancer (Auckl)· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the clinical utility and impact on healthcare utilization of serial troponin T monitoring in gynecologic cancer patients receiving immune checkpoint inhibitors - A single centre experience.
Italo Fernandes, Anjali Sachdeva, Farideh Tavangar, Matthew Lafreniere, Paul Yip, Helen MacKay

Gynecol Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Surgery versus definitive radiotherapy in the management of stage I-II small cell neuroendocrine carcinoma of the cervix: A systematic review and meta-analysis.
Kevin Yijun Fan, Rania Chehade, Andrew Yuanbo Wang, Anjali Sachdeva, Farideh Tavangar, Helen J MacKay

Gynecol Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized study evaluating optimal dose, efficacy, and safety of E7386 plus lenvatinib versus treatment of physician's choice in advanced/recurrent endometrial carcinoma previously treated with platinum-based chemotherapy and immune checkpoint inhibitors.
Ramez N Eskander, Jung-Yun Lee, Mansoor Raza Mirza, Domenica Lorusso, Helen MacKay

Int J Gynecol Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial.
Charles A Leath, Wei Deng, Loren K Mell, Debra L Richardson, Joan L Walker, Helen MacKay

Gynecol Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TIP25-243: Randomized Study Evaluating Optimal Dose, Efficacy and Safety of E7386 + Lenvatinib Versus Treatment of Physicians' Choice in Advance/Recurrent Endometrial Carcinoma Previously Treated With Anti-PD-(L)1 Immunotherapy.
Ramez Eskander, Jung-Yun Lee, Mansoor Mirza, Domenica Lorusso, Helen Mackay

J Natl Compr Canc Netw· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Putting Patients First: Pragmatic Trials in Gynecologic Oncology.
Laura Hopkins, Mark Clemons, Karen Bemister, Chris Booth, Shannon Kadar, Helen MacKay

Curr Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances in Vulvar Cancer Biology and Management.
Rania Chehade, Katarzyna J Jerzak, Farideh Tavanger, Anna Plotkin, Lilian T Gien, Helen Mackay

J Clin Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005.
Jung-Min Lee, Mark F Brady, Austin Miller, Richard G Moore, Helen MacKay

J Clin Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cell-free DNA in recurrent and metastatic endometrial cancer: The future is now? Promises and potential pitfalls.
Helen MacKay, Italo Fernandes

Cancer· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of recurrence risk in endometrial cancer with multimodal deep learning.
Sarah Volinsky-Fremond, Nanda Horeweg, Sonali Andani, Jurriaan Barkey Wolf, Maxime W Lafarge, Helen Mackay

Nat Med· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Prediction of recurrence risk in endometrial cancer with multimodal deep learning.
Sarah Volinsky-Fremond, Nanda Horeweg, Sonali Andani, Jurriaan Barkey Wolf, Maxime W Lafarge, Helen Mackay

Nat Med· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PARP inhibitors in non-ovarian gynecologic cancers.
Italo Fernandes, Rania Chehade, Helen MacKay

Ther Adv Med Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world outcomes associated with bevacizumab combined with chemotherapy in platinum-resistant ovarian Cancer.
Gordon Taylor Moffat, Weidong Kong, Helen J MacKay, Jacob McGee, Christopher M Booth

Gynecol Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pan-Canadian Analysis of Practice Patterns in Small Cell Carcinoma of the Cervix: Insights from a Multidisciplinary Survey.
Kevin Yijun Fan, Rania Chehade, Andrew Yuanbo Wang, Anjali Sachdeva, Helen J MacKay

Curr Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer.
Bobbie J Rimel, Danielle Enserro, David P Bender, Camille Gunderson Jackson, Annie Tan, Helen MacKay

Cancer· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Validation of Human Papilloma Virus Circulating Tumor DNA for Early Detection of Residual Disease After Chemoradiation in Cervical Cancer.
Kathy Han, Jinfeng Zou, Zhen Zhao, Zeynep Baskurt, Yangqiao Zheng, Helen Mackay

J Clin Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Third-line treatment patterns in HER2-positive metastatic breast cancer: a retrospective analysis of real-world data in Canada.
Karen Gambaro, Mélanie Groleau, Suzan McNamara, Arif Awan, Maged Salem, Helen MacKay

J Pharm Pharm Sci· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of the Wee1 kinase inhibitor adavosertib (AZD1775) in combination with chemoradiation in cervical, upper vaginal, and uterine cancers.
Eduardo Gonzalez-Ochoa, Michael Milosevic, Bradley Corr, James L Abbruzzese, Eugenia Girda, Helen Mackay

Int J Gynecol Cancer· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world outcomes associated with use of front-line bevacizumab in ovarian cancer.
Josee-Lyne Ethier, Weidong Kong, Helen J MacKay, Jacob McGee, Christopher M Booth

J Cancer Policy· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775.
Vicky Makker, Nicoletta Colombo, Antonio Casado Herráez, Bradley J Monk, Helen Mackay

J Clin Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry.
Lisa Vermij, Jan J Jobsen, Alicia León-Castillo, Mariel Brinkhuis, Suzan Roothaan, Helen J Mackay

Br J Cancer· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcome and biomarker assessments of a multi-centre phase II trial assessing niraparib with or without dostarlimab in recurrent endometrial carcinoma.
Ainhoa Madariaga, Swati Garg, Nairi Tchrakian, Neesha C Dhani, Waldo Jimenez, Helen MacKay

Nat Commun· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and eosin-stained whole-slide images: a combined analysis of the PORTEC randomised trials and clinical cohorts.
Sarah Fremond, Sonali Andani, Jurriaan Barkey Wolf, Jouke Dijkstra, Sinéad Melsbach, Helen J Mackay

Lancet Digit Health· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality-of-Life Outcomes and Toxic Effects Among Patients With Cancers of the Uterus Treated With Stereotactic Pelvic Adjuvant Radiation Therapy: The SPARTACUS Phase 1/2 Nonrandomized Controlled Trial.
Eric Leung, Adam P Gladwish, Melanie Davidson, Amandeep Taggar, Vikram Velker, Helen MacKay

JAMA Oncol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis